NightHawk Biosciences Receivables

NightHawk Biosciences posts a receivables of $180B as of September 2025. That compares with $200B in the prior-year period — down 11.4% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, NightHawk Biosciences's receivables was $200B. The latest reading is $180B — a 11.4% year-over-year decrease (period ending September 2025). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of NightHawk Biosciences's financial statement story. At $180B, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for NHWK's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; NightHawk Biosciences's other metric pages and overview cover the third.

Judging NightHawk Biosciences against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in receivables easier to interpret. Start with $180B here, then scan peer and history charts to see if the gap is persistent.